9 Nov 2018 07:00
MedaPhor Group plc
("MedaPhor" or the "Company")
MedaPhor assists the INTERGROWTH-21st Project at the University of Oxford
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, has provided valuable assistance to The International Fetal and Newborn Growth (INTERGROWTH-21st) Consortium led by the University of Oxford.
The Consortium has developed new international standards describing optimal fetal and newborn growth, which are being incorporated into clinical care around the world to improve health outcomes.
The INTERGROWTH-21st Project involved collecting data throughout pregnancy, including over 500,000 fetal ultrasound images, from healthy women in eight geographically diverse regions of the world.
To classify the anatomical structures in those images automatically, the Consortium applied MedaPhor's ScanNav® intelligent ultrasound technology, which uses AI algorithms and deep learning techniques to achieve over 99% accuracy.
Professor Stephen Kennedy, Head of the Nuffield Department of Women's & Reproductive Health at the University of Oxford and Co-Principal Investigator of the INTERGROWTH-21st Project, commented: "ScanNav has categorised the Project's massive ultrasound database in a way that would have been impracticable with human curation. Deep mining of the data has been made much easier."
Dr Mohammad Yaqub, VP Engineering at MedaPhor, commented: "We have not only catalogued the INTERGROWTH-21st ultrasound database, but also demonstrated that ScanNav can classify fetal scans accurately in both the second and third trimesters of pregnancy. We hope the curation we have produced will help researchers in the future."
For more information about MedaPhor's clinical products currently in development visit www.intelligentultrasound.com
MedaPhor Group plc | www.medaphor.com | |
Stuart Gall, CEO Ian Whittaker, COO | Tel: +44 (0)29 2075 6534 | |
Cenkos Securities | Tel: +44 (0)20 7397 8900 | |
Mark Connelly / Cameron MacRitchie (Nominated Advisor) | ||
Michael Johnson / Julian Morse (Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com | |
Anna Dunphy / Paul McManus | Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893 | |
About MedaPhor (www.investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK, Atlanta in the US and Hong Kong in Asia, MedaPhor operates two divisions:
Intelligent Ultrasound Simulation Division
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Eve Point of Care and Emergency Medicine Simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound Clinical Division
Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav and NeedleGuide. ScanNav uses machine-learning based algorithms to automatically identify, grade and capture good ultrasound images. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.
Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.